Editorial introductions : Current Opinion in Neurology

Secondary Logo

Journal Logo

EDITORIAL INTRODUCTIONS

Editorial introductions

Editor(s): Tamburin, Stefano; Touat, Mehdi

Current Opinion in Neurology: December 2022 - Volume 35 - Issue 6 - p v-vi
doi: 10.1097/WCO.0000000000001121
  • Free

Current Opinion in Neurology was launched in 1988. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of neurology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

SECTION EDITORS

Stefano Tamburin

figure1
Stefano Tamburin

Stefano Tamburin, MD, PhD, is Associate Professor of Neurology at the Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy. He is Director of the Master Course in Clinical and Experimental Neuropsychology, and member of the teaching staff of the School of Medicine, the PhD School of Neurosciences, Psychological, Psychiatric and Movement Sciences, and the Neurology Residency School, University of Verona. He graduated summa cum laude at the University of Ferrara Medical School, Italy, and completed his neurology residency at the University of Verona, Medical School, where he obtained his PhD in Neuroscience.

His main areas of research include the pathophysiology of neurodegenerative diseases, the motor and cognitive outcomes of stroke and neurological diseases, and the cognitive effects of brain aging. Other areas of research include peripheral nervous system diseases, neuropathic pain, central and peripheral neurotoxicity to cancer therapy. The experimental approach is integrative and translational and includes clinical neurophysiology, neuroimaging, neurorehabilitation, neuropsychology and psychophysics, advanced diagnostic and therapeutic technologies and the use of engineering and computer tools (information and communication technology, internet of the medical things, artificial intelligence) to improve diagnosis and therapy. He authored more than 180 publications in international peer reviewed journals (Scopus h-index: 34). He received the 2005 Melvin Yahr Memorial Fellowship Award (The International Federation of Parkinson's Disease, New York) and the 2010 European Federation of IASP® Chapters (EFIC) – Grünenthal Grant Prize for clinical and human experimental pain research.

His clinical interests include neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, parkinsonism and dementia), neurorehabilitation, neuropathic pain and peripheral nervous system diseases.

He served as Secretary of the Neuropathic Pain Consortium and is Board Member of the Toxic Neuropathy Consortium of the Peripheral Nerve Society, and Co-Chair of the Neurological Complications, Biomarkers and Preclinical Work subgroup of the Multinational Association of Supportive Care in Cancer. He is Secretary of the Italian Society of Neurorehabilitation and Board Member of the Italian Association for the Study of Pain. He served in the Board of Directors of the Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN).

Mehdi Touat

figure2
Mehdi Touat

Mehdi Touat, MD, PhD, is a neuro-oncologist at the Pitié-Salpêtrière Hospital in Paris and principal investigator at the Paris Brain Institute, France. He is an Assistant Professor of Neurology at Sorbonne University in Paris, France, with adjunct appointment in the Neurology department of the Brigham and Women's Hospital in Boston. He completed his clinical training in neurology and medical oncology at Sorbonne University and gained a PhD in the field of Cancer Biology and Genomics from Paris Saclay University, France. He did a three-year research fellowship on glioma evolution and resistance to chemotherapy and immunotherapy at the Dana-Farber Cancer Institute in Boston.

His work is directed at finding more effective therapies for CNS tumors, especially gliomas. This effort is particularly focused on developing novel immune-oncology approaches, early clinical development and precision medicine trials for malignant primary brain tumors. He is a member of the EORTC General Assembly and of the EORTC Brain Tumor Group. He is a peer reviewer for several international journals and published papers as first or last author in the journals Nature, Journal of Clinical Oncology, Annals of Oncology, Journal of Clinical Investigations and Clinical Cancer Research.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.